{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T13:17:19Z","timestamp":1784207839033,"version":"3.55.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,16]]},"DOI":"10.7759\/cureus.112781","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:55:40Z","timestamp":1784206540000},"source":"Crossref","is-referenced-by-count":0,"title":["Mesalazine Nonadherence in Mild-to-Moderate Ulcerative Colitis: Barriers in a Moroccan Cohort"],"prefix":"10.7759","author":[{"given":"Jihane","family":"Rizkou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatimaezzahra","family":"Lairani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oussama","family":"Nacir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adil","family":"Ait errami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Oubaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zouhour","family":"Samlani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khadija","family":"Krati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine T","year":"2022","unstructured":"Raine T, Bonovas S, Burisch J, et al.. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2022, 16:2-17. 10.1093\/ecco-jcc\/jjab178","journal-title":"J Crohns Colitis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.12.009","article-title":"AGA clinical practice guidelines on the management of mild-to-moderate ulcerative colitis","volume":"156","author":"Ko CW","year":"2019","unstructured":"Ko CW, Singh S, Feuerstein JD, Falck-Ytter C, Falck-Ytter Y, Cross RK. AGA clinical practice guidelines on the management of mild-to-moderate ulcerative colitis. Gastroenterology. 2019, 156:748-64. 10.1053\/j.gastro.2018.12.009","journal-title":"Gastroenterology"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.04683.x","article-title":"Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis","volume":"96","author":"Kane SV","year":"2001","unstructured":"Kane SV, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001, 96:2929-33. 10.1111\/j.1572-0241.2001.04683.x","journal-title":"Am J Gastroenterol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(02)01383-9","article-title":"Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis","volume":"114","author":"Kane S","year":"2003","unstructured":"Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003, 114:39-43. 10.1016\/S0002-9343(02)01383-9","journal-title":"Am J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S127039","article-title":"Adherence in ulcerative colitis: an overview","volume":"11","author":"Testa A","year":"2017","unstructured":"Testa A, Castiglione F, Nardone OM, Colombo GL. Adherence in ulcerative colitis: an overview. Patient Prefer Adherence. 2017, 11:297-303. 10.2147\/PPA.S127039","journal-title":"Patient Prefer Adherence"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/jpm15040123","article-title":"Non-adherence rate to oral mesalamine in ulcerative colitis patients: a systematic review with meta-analysis","volume":"15","author":"Pagnini C","year":"2025","unstructured":"Pagnini C, Antonelli E, Scrivo B, et al.. Non-adherence rate to oral mesalamine in ulcerative colitis patients: a systematic review with meta-analysis. J Pers Med. 2025, 15:123. 10.3390\/jpm15040123","journal-title":"J Pers Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03698.x","article-title":"Review article: medication non-adherence in ulcerative colitis-strategies to improve adherence with mesalazine and other maintenance therapies","volume":"27","author":"Hawthorne AB","year":"2008","unstructured":"Hawthorne AB, Rubin G, Ghosh S. Review article: medication non-adherence in ulcerative colitis-strategies to improve adherence with mesalazine and other maintenance therapies. Aliment Pharmacol Ther. 2008, 27:1157-66. 10.1111\/j.1365-2036.2008.03698.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.685","article-title":"Factors associated with non-adherence to oral medication for inflammatory bowel disease: a systematic review","volume":"105","author":"Jackson CA","year":"2010","unstructured":"Jackson CA, Clatworthy J, Robinson A, Horne R. Factors associated with non-adherence to oral medication for inflammatory bowel disease: a systematic review. Am J Gastroenterol. 2010, 105:525-39. 10.1038\/ajg.2009.685","journal-title":"Am J Gastroenterol"},{"key":"ref9","article-title":"Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis","volume":"106","author":"Ford AC","year":"2011","unstructured":"Ford AC, Khan KJ, Achkar JP, Moayyedi P. Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2011, 106:2070-7.","journal-title":"Am J Gastroenterol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.23024","article-title":"Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: a systematic review and meta-analysis","volume":"18","author":"Feagan BG","year":"2012","unstructured":"Feagan BG, MacDonald JK. Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: a systematic review and meta-analysis. Inflamm Bowel Dis. 2012, 18:1785-94. 10.1002\/ibd.23024","journal-title":"Inflamm Bowel Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2018.00064","article-title":"Adherence to Asacol once daily versus divided regimen for maintenance therapy in ulcerative colitis: a prospective, multicenter, randomized study","volume":"17","author":"Park SK","year":"2019","unstructured":"Park SK, Park SH, Eun CS, Seo GS, Im JP, Kim TO, Park DI. Adherence to Asacol once daily versus divided regimen for maintenance therapy in ulcerative colitis: a prospective, multicenter, randomized study. Intest Res. 2019, 17:349-56. 10.5217\/ir.2018.00064","journal-title":"Intest Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2147\/CEG.S237653","article-title":"Patient preference and adherence to aminosalicylates for the treatment of ulcerative colitis","volume":"14","author":"Tripathi K","year":"2021","unstructured":"Tripathi K, Dong J, Mishkin BF, Feuerstein JD. Patient preference and adherence to aminosalicylates for the treatment of ulcerative colitis. Clin Exp Gastroenterol. 2021, 14:343-51. 10.2147\/CEG.S237653","journal-title":"Clin Exp Gastroenterol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000544.pub5","article-title":"Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis","volume":"8","author":"Murray A","year":"2020","unstructured":"Murray A, Nguyen TM, Parker CE, Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2020, 8:CD000544. 10.1002\/14651858.CD000544.pub5","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/513933-mesalazine-nonadherence-in-mild-to-moderate-ulcerative-colitis-barriers-in-a-moroccan-cohort","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:55:41Z","timestamp":1784206541000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/513933-mesalazine-nonadherence-in-mild-to-moderate-ulcerative-colitis-barriers-in-a-moroccan-cohort"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.112781","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,16]]}}}